Market news

PTC Therapeutics (PTCT) said late Monday it completed the acquisition of ST-920, a gene therapy for

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene therapy for Fabry disease. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026.

PTC Therapeutics (PTCT) heads into its next earnings report with consensus EPS forecasts unchanged over the past month, even as the stock ticked 0.6% higher in the last session to close at $68. Recent trading has been choppy for PTC Therapeutics, with the share price down 3.9% over the last session to $65.37 and weaker momentum over the past quarter. However, the 3-year total shareholder return of 173.3% and 5-year total shareholder return of 66.4% still reflect a materially stronger long-run...

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28. The presentations include new data from clinical trials and real-world evidence which reinforce the clinically meaningful benefits of Sephience on lowering phenylalanine (Phe), significant diet liberalization and sust

PTC Therapeutics (PTCT) risk-reward: Sephience revenue growth and potential ST-920 Fabry gene therapy FDA approval could lift valuation.

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. The terms include $111 million upfront and up to $100 million in contingent milestone payments based on certain regulatory approvals. A rolling BLA submission to FDA for accelerated approval of ST-920 is expected to be completed in Q4 2026. The BLA

Recent analysis of PTC Therapeutics points to price targets clustering in a broad band that runs from the mid US$80s up to US$130. Analysts link these higher targets to supportive views on Sephience performance, expectations for the broader pipeline, and debate over how much of that potential is already reflected in the current share price. As you read on, you will see how these shifting targets fit into the wider narrative and how to track the story as it develops. Analyst Price Targets...

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold players in this sector.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics (NASDAQ:PTCT) reported second-quarter total revenue of $361 million and raised its 2026 outlook, citing continued growth from its Sephience launch and greater durability than expected in its Duchenne muscular dystrophy franchise. Chief Executive Officer Dr. Matthew Klein said the c

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ended June 30, 2026.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Ptc Therapeutics (PTCT-Q) from The Globe and Mail including charting and trades.

WARREN, N.J. , July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's b...

This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities.